MONTREAL, QUEBEC--(Marketwire - February 05, 2008) - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced that it has completed patient enrollment for the Phase II trial of CAP-232 in refractory renal cell carcinoma patients. The open label trial was designed to assess the safety and pharmacokinetic profile of Thallion’s new continuous intravenous formulation of CAP-232, as well as provide efficacy data in patients who had failed to benefit from the current standard of care. The trial was designed to administer 0.48 mg/kg/day of CAP-232 through continuous intravenous infusion for three cycles, each cycle consisting of 21 days of treatment followed by seven days of rest.
